A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of JADE101 Administered Subcutaneously in Participants With Immunoglobulin A Nephropathy (The EVERGREEN Study)

Inclusion Criteria: 1. Adult participants with biopsy-confirmed primary IgAN. 2. UPCR ≥0.75 g/g or 24-hour protein excretion ≥1 g/day, as measured from an adequately collected 24-hour urine sample. 3. eGFR ≥30 mL/min/1.73 m². 4. Stable and maximally tolerated doses of ACEi and/or ARB according to standard of care and applicable guidelines for at least 12 weeks prior to the initial screening visit. Exclusion Criteria: 1. Secondary forms of IgAN, or ongoing IgA vasculitis (Henoch-Schönlein purpura) with systemic involvement requiring immunosuppressive treatment. 2. Known or clinically suspect…